<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724812</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10260</org_study_id>
    <nct_id>NCT03724812</nct_id>
  </id_info>
  <brief_title>FlexNav EU CE Mark Study</brief_title>
  <official_title>Assessment of the Abbott FlexNav™ Delivery System for Portico Transcatheter Aortic Valve Implantation in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to characterize the safety of the&#xD;
      next-generation FlexNav™ Delivery System for transfemoral implantation of the Portico™&#xD;
      Transcatheter Aortic Heart Valve in symptomatic severe aortic stenosis patients who are&#xD;
      considered of high or extreme risk for surgical aortic valve replacement. Data from the study&#xD;
      will be used to support CE Mark of the FlexNav™ Delivery System and Loading System in Europe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FlexNav European Union (EU) study will be conducted as a prospective, multi-center,&#xD;
      single-arm investigational study.&#xD;
&#xD;
      High or extreme risk patients with symptomatic, severe native aortic stenosis who are&#xD;
      determined by an independent subject selection committee to meet eligibility criteria for&#xD;
      Portico™ Transcatheter Aortic Heart Valve implantation via a transfemoral access approach&#xD;
      will undergo a Portico valve implant using the next-generation FlexNav Delivery System.&#xD;
&#xD;
      Subject data will be collected at screening, baseline, pre-procedure, peri-procedure,&#xD;
      post-procedure, discharge, 30 days, 6 months and 1-year from the index procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">January 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Devices under investigation in this clinical investigation include the FlexNav™ Delivery System(s) (18 F and 19 F) and FlexNav™ Loading System(s) (Small and Large), which are both approved for investigational use only. Other devices to be used in the clinical investigation include all four (4) market released Abbott Portico™ valve sizes (23mm, 25mm, 27mm and 29mm).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Vascular Complications</measure>
    <time_frame>At 30 days post index procedure</time_frame>
    <description>Percentage of patients with a VARC-2 defined major vascular complication event</description>
  </primary_outcome>
  <other_outcome>
    <measure>Non-hierarchical Composite Safety Endpoint</measure>
    <time_frame>30 days from the index procedure.</time_frame>
    <description>Percentage of patients with a non-hierarchical composite endpoint of all-cause mortality, disabling stroke, life threatening bleeding requiring blood transfusion, acute kidney injury requiring dialysis, or major vascular complications</description>
  </other_outcome>
  <other_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>30 days from the index procedure</time_frame>
    <description>Percentage of patients with VARC 2 defined all-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Disabling Stroke</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Percentage of patients with a VARC-2 defined disabling stroke event</description>
  </other_outcome>
  <other_outcome>
    <measure>Life-threatening Bleeding Requiring Blood Transfusion</measure>
    <time_frame>30 days from the index procedure</time_frame>
    <description>Percentage of patients with a VARC-2 defined life-threatening bleeding event requiring blood transfusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Bleeding Event</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Percentage of patients with VARC 2 defined major bleeding event</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Percentage of patients with a VARC 2 defined acute kidney injury event</description>
  </other_outcome>
  <other_outcome>
    <measure>Minor Vascular Complication</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Percentage of patients with a VARC-2 defined minor vascular complication</description>
  </other_outcome>
  <other_outcome>
    <measure>New Permanent Pacemaker Implant</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Percentage of patients requiring a new permanent pacemaker. Excludes patients with a pre-existing permanent pacemaker at baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of Paravalvular Leak</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Echocardiographic core-laboratory derived severity of paravalvular leak</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Classification</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>Proportion of subjects with a NYHA Functional Class of I,II, III or IV (range I-IV where a lower score indicates less limitation in physical activity)</description>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire Quality of Life (QOL) Score</measure>
    <time_frame>30 days from index procedure</time_frame>
    <description>KCCQ Overall summary score (range 0-100 where a higher score indicates a better quality of life and physical function)</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical Device Success</measure>
    <time_frame>Over the duration of index procedure, an average of 60.6 minutes</time_frame>
    <description>Technical device success defined as successful vascular access, delivery and deployment of the Portico Valve; retrieval with the delivery system and correct positioning of a single valve in the proper anatomical location.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Symptomatic Severe Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Portico valve and FlexNav™ Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Portico valve implantation with the second-generation FlexNav Delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portico Valve and FlexNav™ Delivery System</intervention_name>
    <description>Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach</description>
    <arm_group_label>Portico valve and FlexNav™ Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Candidates for High Risk classification must meet all the following inclusion criteria:&#xD;
&#xD;
          1. Subjects must have co-morbidities such that the local heart team concur the predicted&#xD;
             risk of operative mortality is ≥15% or a minimum Society of Thoracic Surgeons (STS)&#xD;
             score of 8%.&#xD;
&#xD;
             a) A candidate who does not meet the STS score criteria of ≥ 8% may be included in the&#xD;
             study if at least one surgeon in the local heart team concludes and documents the&#xD;
             patient's predicted risk of operative mortality is ≥15%. The surgeon's assessment of&#xD;
             operative comorbidities (including frailty indices) not captured by the STS score must&#xD;
             be documented in the study case report form as well as in the patient medical record.&#xD;
&#xD;
          2. Subject is of legal age or older for consent in the host country.&#xD;
&#xD;
          3. Subject has senile degenerative aortic valve stenosis with echo-derived criteria: mean&#xD;
             gradient &gt;40 mmHg or jet velocity greater than 4.0 m/s or doppler velocity index (DVI)&#xD;
             &lt;0.25 and an initial aortic valve area (AVA) of ≤1.0 cm2 (indexed Effective Orifice&#xD;
             Area (EOA) ≤ 0.6 cm2/m2). (Qualifying AVA baseline measurement must be within 60 days&#xD;
             prior to informed consent).&#xD;
&#xD;
          4. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional&#xD;
             Classification of II, III, or IV.&#xD;
&#xD;
          5. The subject has been informed of the nature of the study, agrees to its provisions and&#xD;
             has provided written informed consent as approved by the Institutional Review Board&#xD;
             (IRB) of the respective clinical site.&#xD;
&#xD;
          6. The subject and the treating physician agree that the subject will return for all&#xD;
             required post-procedure follow-up visits.&#xD;
&#xD;
          7. Subject's aortic annulus is 19-27mm diameter as measured by computed tomography (CT)&#xD;
             conducted within 12 months prior to informed consent. If a CT i contraindicated and/or&#xD;
             not possible to be obtained for certain subjects, a 3D echo and non-contrast CT of&#xD;
             chest and abdomen/pelvis may be accepted.&#xD;
&#xD;
             All candidates for Extreme Risk classification must meet # 2, 3, 4, 5, 6, 7 of the&#xD;
             above criteria, and&#xD;
&#xD;
          8. After formal consultation with the local heart team (including at least one surgeon)&#xD;
             it is agreed that medical factors preclude the subject from undergoing operation,&#xD;
             based on a conclusion that the probability of death or serious, irreversible morbidity&#xD;
             exceeds the probability of meaningful improvement. Specifically, the probability of&#xD;
             death or serious, irreversible morbidity should exceed 50%. The local heart teams'&#xD;
             consult notes shall specify the medical or anatomic factors leading to that conclusion&#xD;
             and include a printout of the calculation of the STS score to additionally identify&#xD;
             the risks in these patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidates will be excluded if any of the following conditions are present:&#xD;
&#xD;
          1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as&#xD;
             evidenced on 12 Lead ECG) within 30 days prior to index procedure.&#xD;
&#xD;
          2. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is&#xD;
             noncalcified as verified by echocardiography.&#xD;
&#xD;
          3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant&#xD;
             aortic regurgitation 3-4+).&#xD;
&#xD;
          4. Any percutaneous coronary or peripheral interventional procedure performed within 30&#xD;
             days prior to index procedure.&#xD;
&#xD;
          5. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic&#xD;
             ring, severe circumferential mitral annular calcification (MAC) which is continuous&#xD;
             with calcium in the LVOT, severe (greater than 3+) mitral insufficiency, or severe&#xD;
             mitral stenosis with pulmonary compromise.&#xD;
&#xD;
          6. Blood dyscrasias as defined: leukopenia (WBC&lt;3000 mm3), acute anemia (Hb &lt; 9 g/dL),&#xD;
             thrombocytopenia (platelet count &lt;50,000 cells/mm³).&#xD;
&#xD;
          7. History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          8. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or&#xD;
             mechanical hemodynamic support.&#xD;
&#xD;
          9. Untreated clinically significant coronary artery disease requiring revascularization.&#xD;
&#xD;
         10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.&#xD;
&#xD;
         11. Need for emergency surgery for any reason.&#xD;
&#xD;
         12. Hypertrophic cardiomyopathy with or without obstruction (HOCM).&#xD;
&#xD;
         13. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) &lt;20% as&#xD;
             measured by resting echocardiogram.&#xD;
&#xD;
         14. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.&#xD;
&#xD;
         15. Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure.&#xD;
&#xD;
         16. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine&#xD;
             (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be&#xD;
             adequately premedicated.&#xD;
&#xD;
         17. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA)&#xD;
             or a transient ischemic attack (TIA).&#xD;
&#xD;
         18. Renal insufficiency (creatinine &gt; 3.0 mg/dL) and/or end stage renal disease requiring&#xD;
             chronic dialysis.&#xD;
&#xD;
         19. Life expectancy &lt; 12 months from the time of informed consent due to noncardiac&#xD;
             co-morbid conditions.&#xD;
&#xD;
         20. Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as&#xD;
             maximal luminal diameter 5cm or greater; marked tortuosity (hyperacute bend), aortic&#xD;
             arch atheroma (especially if thick [&gt; 5 mm], protruding or ulcerated) or narrowing&#xD;
             (especially with calcification and surface irregularities) of the abdominal or&#xD;
             thoracic aorta, severe &quot;unfolding&quot; and tortuosity of the thoracic aorta.&#xD;
&#xD;
         21. Native aortic annulus size &lt; 19 mm or &gt; 27 mm per the baseline diagnostic imaging.&#xD;
&#xD;
         22. Aortic root angulation &gt; 70°.&#xD;
&#xD;
         23. Currently participating in an investigational drug or device study.&#xD;
&#xD;
         24. Active bacterial endocarditis within 6 months prior to the index procedure.&#xD;
&#xD;
         25. Bulky calcified aortic valve leaflets in close proximity to coronary ostia.&#xD;
&#xD;
         26. Non-calcified aortic annulus.&#xD;
&#xD;
         27. Iliofemoral vessel characteristics that would preclude safe insertion of the FlexNav™&#xD;
             delivery system with or without an arterial introducer sheath such as severe&#xD;
             obstructive calcification, or severe tortuosity.&#xD;
&#xD;
         28. In the judgment of the investigator, a condition that could limit a patient's ability&#xD;
             or willingness to participate in the study, comply with study required testing and/or&#xD;
             follow- up visits or that could impact scientific integrity of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bedogni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico San Donato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Lombard</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets Spital Zuerich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital - ABM University Health Board</name>
      <address>
        <city>Morriston</city>
        <state>Swansea</state>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <results_first_submitted>January 13, 2021</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>FlexNav™ Delivery System</keyword>
  <keyword>Portico Delivery System</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Heart Valve Disease</keyword>
  <keyword>High surgical risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03724812/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03724812/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between 26 February 2019 and 10 December 2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Portico Valve and FlexNav™ Delivery System</title>
          <description>Subjects will undergo an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and next-generation FlexNav Delivery system via a transfemoral access approach</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30 Days Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population includes subjects that underwent an attempted Portico valve implant with the FlexNav delivery system</population>
      <group_list>
        <group group_id="B1">
          <title>Portico Valve and FlexNav™ Delivery System</title>
          <description>Subjects will undergo an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and next-generation FlexNav Delivery system via a transfemoral access approach</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Vascular Complications</title>
        <description>Percentage of patients with a VARC-2 defined major vascular complication event</description>
        <time_frame>At 30 days post index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complications</title>
          <description>Percentage of patients with a VARC-2 defined major vascular complication event</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.5" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Non-hierarchical Composite Safety Endpoint</title>
        <description>Percentage of patients with a non-hierarchical composite endpoint of all-cause mortality, disabling stroke, life threatening bleeding requiring blood transfusion, acute kidney injury requiring dialysis, or major vascular complications</description>
        <time_frame>30 days from the index procedure.</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Non-hierarchical Composite Safety Endpoint</title>
          <description>Percentage of patients with a non-hierarchical composite endpoint of all-cause mortality, disabling stroke, life threatening bleeding requiring blood transfusion, acute kidney injury requiring dialysis, or major vascular complications</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="1.37" upper_limit="17.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All-Cause Mortality</title>
        <description>Percentage of patients with VARC 2 defined all-cause mortality</description>
        <time_frame>30 days from the index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality</title>
          <description>Percentage of patients with VARC 2 defined all-cause mortality</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Disabling Stroke</title>
        <description>Percentage of patients with a VARC-2 defined disabling stroke event</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Disabling Stroke</title>
          <description>Percentage of patients with a VARC-2 defined disabling stroke event</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Life-threatening Bleeding Requiring Blood Transfusion</title>
        <description>Percentage of patients with a VARC-2 defined life-threatening bleeding event requiring blood transfusion</description>
        <time_frame>30 days from the index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Life-threatening Bleeding Requiring Blood Transfusion</title>
          <description>Percentage of patients with a VARC-2 defined life-threatening bleeding event requiring blood transfusion</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.53" upper_limit="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Bleeding Event</title>
        <description>Percentage of patients with VARC 2 defined major bleeding event</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Event</title>
          <description>Percentage of patients with VARC 2 defined major bleeding event</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.53" upper_limit="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Acute Kidney Injury</title>
        <description>Percentage of patients with a VARC 2 defined acute kidney injury event</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Kidney Injury</title>
          <description>Percentage of patients with a VARC 2 defined acute kidney injury event</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Minor Vascular Complication</title>
        <description>Percentage of patients with a VARC-2 defined minor vascular complication</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Minor Vascular Complication</title>
          <description>Percentage of patients with a VARC-2 defined minor vascular complication</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="6.34" upper_limit="28.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Permanent Pacemaker Implant</title>
        <description>Percentage of patients requiring a new permanent pacemaker. Excludes patients with a pre-existing permanent pacemaker at baseline</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects) and who did not have a pre-existing pacemaker at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects without a permanent pacemaker at baseline that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>New Permanent Pacemaker Implant</title>
          <description>Percentage of patients requiring a new permanent pacemaker. Excludes patients with a pre-existing permanent pacemaker at baseline</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects) and who did not have a pre-existing pacemaker at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="5.43" upper_limit="28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severity of Paravalvular Leak</title>
        <description>Echocardiographic core-laboratory derived severity of paravalvular leak</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects) with an analyzable echocardiogram at 30 days</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Paravalvular Leak</title>
          <description>Echocardiographic core-laboratory derived severity of paravalvular leak</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects) with an analyzable echocardiogram at 30 days</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None/Trace/Trivial PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe PVL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Classification</title>
        <description>Proportion of subjects with a NYHA Functional Class of I,II, III or IV (range I-IV where a lower score indicates less limitation in physical activity)</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects). Information was not available for one subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Classification</title>
          <description>Proportion of subjects with a NYHA Functional Class of I,II, III or IV (range I-IV where a lower score indicates less limitation in physical activity)</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects). Information was not available for one subject.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kansas City Cardiomyopathy Questionnaire Quality of Life (QOL) Score</title>
        <description>KCCQ Overall summary score (range 0-100 where a higher score indicates a better quality of life and physical function)</description>
        <time_frame>30 days from index procedure</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects). Information was not available for 2 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Kansas City Cardiomyopathy Questionnaire Quality of Life (QOL) Score</title>
          <description>KCCQ Overall summary score (range 0-100 where a higher score indicates a better quality of life and physical function)</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects). Information was not available for 2 subjects.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.46" spread="20.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Technical Device Success</title>
        <description>Technical device success defined as successful vascular access, delivery and deployment of the Portico Valve; retrieval with the delivery system and correct positioning of a single valve in the proper anatomical location.</description>
        <time_frame>Over the duration of index procedure, an average of 60.6 minutes</time_frame>
        <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Portico Valve and FlexNav™ Delivery System</title>
            <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Device Success</title>
          <description>Technical device success defined as successful vascular access, delivery and deployment of the Portico Valve; retrieval with the delivery system and correct positioning of a single valve in the proper anatomical location.</description>
          <population>Analysis population included all subjects in whom a Portico valve implant was attempted (enrolled subjects)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Site-reported adverse events within 30 days of the index procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Portico Valve and FlexNav™ Delivery System</title>
          <description>Subjects that underwent an attempted transcatheter aortic valve replacement (TAVR) with the Portico valve and FlexNav Delivery system via a transfemoral access approach</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pericardial Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Site Complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>General</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>General</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arterial Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dental Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alicia Kimber, PhD</name_or_title>
      <organization>Abbott</organization>
      <phone>+1 415 917 9696</phone>
      <email>alicia.kimber@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

